As per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines' board approved its Q1 FY26 unaudited financial results on 14 August 2025. Revenue from operations nearly doubled to Rs. 145.66 lakh from Rs. 72.49 lakh in the same quarter last year, an increase of about 101%. However, the company continued to post a loss, though the loss after tax narrowed to Rs. 31.04 lakh from Rs. 36.62 lakh a year ago. Total expenses rose to Rs. 179.08 lakh, driven mainly by higher raw material costs (Rs. 103.84 lakh vs Rs. 55.09 lakh). The statutory auditor, Bahedia & Associates, issued an unqualified limited review report with no qualifications or emphasis of matter. The company reported no exceptional or extraordinary items during the quarter.
Strong top-line growth is a positive signal, but persistent quarterly losses and a full-year FY25 loss of Rs. 123.75 lakh suggest the company is still in the early stages of recovery. Short-term shareholders may see this as improving momentum, though profitability remains the key concern.